

## THE DUDLEY GROUP NHS FOUNDATION TRUST

9/7/18

### Freedom of Information Request 014182

1 - In your Trust, how much did you spend on Biological and biosimilar medicines, in the past financial year ending April 2018 ?

The total spend in 2017/18 financial year ending March 2018 we spent £6,991,558 on Biologics and Biosimilars of the following drugs:

Trastuzumab, Adalimumab, Infliximab, Etanercept, Rituximab

2 – Have you developed a policy on how prescribers can switch their patients to biosimilars and support them in making informed choices to save resources ?

No policy

If yes, please provide details

3 – Do you have any specific plans in place for the launch of biosimilar Adalimumab later in 2018 ?

These are in development and we are using the information provided by the Regional Medicines Optimisation Committee

4 – Are there any agreements in place between you the Provider and CCG that would enable savings in drug costs to be made ? (For example, Gainshare agreements where the benefits associated with more efficient use of medicines not reimbursed through national prices is shared between the Provider and the Clinical Commissioning Group party to the agreement. This included agreements for the switch to biosimilar products)

If “Yes”, then please provide the following details:

Agreement	Name of specific drugs involved	Disease Area	CCG(s) included in the Gainshare agreement	Savings apportioned between Provider and the CCG(s)
1	Infliximab	Rheumatology, Dermatology and GI As per NICE guidance	yes	50:50
2	Etanercept	Rheumatology, Dermatology As per NICE guidance	Yes	50:50
3	Rituximab	Rheumatology as per NICE guidance	yes	50:50
4	Adalimumab	Rheumatology, Dermatology and GI As per NICE guidance	Yes	50:50
5	Trastuzumab	Oncology as per NICE guidance	Not commissioned by CCGs	N/A

5 – Are there any other agreements with a CCG, not included in the above, for the following services ?

None

If “Yes”, then please provide the following details:

Agreement	Disease Area	CCG(s) included in the agreement	Name of specific drugs involved	Type of agreement with the Provider
1	Ophthalmology services (eg wet macular degeneration)			
2	Multiple Sclerosis			
3	Prostate Cancer			
4	Breast Cancer			
5	Haemophilia			